A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.

Status:
Completed

Trial end date:
2010-07-09

Target enrollment:

Participant gender:

The purpose of this study is to characterise the metabolic disposition of radiolabelled GW642444 when administered orally.

Phase 1

GlaxoSmithKline